Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage immuno-oncology company, renowned for its innovation in next-generation cancer immunotherapies. Headquartered in Gaithersburg, MD, Sensei leverages its proprietary TMAb™ (Tumor Microenvironment Activated biologics) platform to develop cutting-edge therapeutics designed to harness the body's immune system against cancer. The company’s leading product candidates include SNS-101, SNS-102, SNS-103, and SNS-201, all of which are conditionally active antibodies targeting different immunosuppressive markers within the tumor microenvironment.
Sensei’s flagship candidate, SNS-101, is designed to block the VISTA (V-domain Ig suppressor of T cell activation) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 is currently undergoing a multi-center Phase 1/2 clinical trial, evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as both a monotherapy and in combination with Regeneron's PD-1 inhibitor, Libtayo® (cemiplimab), in patients with advanced solid tumors. Initial data are promising, showing SNS-101 to be well-tolerated and demonstrating clinical activity, particularly in tumor types typically resistant to PD-1 monotherapy.
Other promising candidates include SNS-102, targeting VSIG-4 (V-Set and Immunoglobulin Domain Containing 4), and SNS-103, targeting CD39 (ecto-nucleoside triphosphate diphosphohydrolase-1), as well as SNS-201, a conditionally active VISTAxCD28 bispecific antibody. The company has established key academic collaborations, including with Brown University, to bolster its research and development efforts.
Financially, Sensei maintains a strong balance sheet with cash reserves projected to fund operations into the second half of 2025. Recent financial updates show reduced R&D and G&A expenses due to strategic restructuring, leading to a narrower net loss. The company is focused on advancing its clinical trials, with expected milestones including initial combination safety and pharmacokinetic data for SNS-101 in early 2024, followed by topline monotherapy data later in the year.
For more information, visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in Citi's 2024 Global Healthcare Conference. The conference will take place from December 3-5 in Miami, FL. As a clinical stage biotechnology company specializing in next-generation cancer therapeutics, Sensei's management team will be present at this significant healthcare industry event.
Sensei Biotherapeutics (NASDAQ: SNSE) reported Q3 2024 financial results and announced an organizational restructuring. The company will reduce its workforce by 46% and close its Rockville research site to focus resources on SNS-101 clinical development. Cash position stands at $47.0 million, expected to fund operations into Q2 2026. Q3 net loss was $7.3 million, with R&D expenses at $4.6 million and G&A expenses at $3.2 million. The Phase 1/2 dose expansion study for SNS-101 is approximately 50% enrolled, with clinical data expected in H1 2025.
Sensei Biotherapeutics (Nasdaq: SNSE) has announced its participation in two major scientific conferences. At PEGS Europe in Barcelona (November 5-7, 2024), Chief Scientific Officer Edward van der Horst will present on SNS-101, a conditionally active monoclonal antibody targeting VISTA in tumor microenvironment. At the SITC 39th Annual Meeting in Houston (November 6-10, 2024), Senior Director F. Donelson Smith will present a poster on spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications.
Sensei Biotherapeutics (Nasdaq: SNSE) announced that it will present preclinical data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference from September 8-11, 2024. The presentation, titled 'Pre-clinical characterization of monoclonal antibodies targeting CD39 activity in the acidic tumor microenvironment,' will be given by F. Donelson Smith, Ph.D., Senior Director of Biologics Discovery & Early Development. The poster session is scheduled for September 8, 2024, from 12:05 – 2:05 p.m. EDT.
Sensei Biotherapeutics is a clinical-stage immuno-oncology company focused on developing next-generation cancer therapeutics. The presentation of preclinical data on SNS-103 suggests ongoing research and development efforts in their pipeline.
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage immuno-oncology company, has announced its participation in two upcoming conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 7:00 a.m. ET, delivering a corporate presentation. Additionally, Sensei will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on September 18 at 2:30 p.m. ET.
Both events will be accessible via webcast on the Investors section of Sensei's website, with replays available for approximately 90 days following the presentations. These conferences provide Sensei Biotherapeutics with opportunities to showcase their progress in developing next-generation cancer therapeutics to investors and industry professionals.
Sensei Biotherapeutics (Nasdaq: SNSE) reported Q2 2024 financial results and business highlights. The company presented promising Phase 1/2 clinical data for SNS-101 at ASCO 2024, demonstrating early signs of clinical activity in immunotherapy-resistant patients. Patient enrollment is advancing in the dose expansion portion of the Phase 1/2 study, with initial data expected in Q4 2024. Sensei's cash position stands at $52.3 million, providing runway into Q4 2025. Financial results show R&D expenses of $4.6 million and G&A expenses of $3.2 million for Q2 2024. The company reported a net loss of $7.1 million, an improvement from $9.4 million in Q2 2023.
Sensei Biotherapeutics, a clinical stage immuno-oncology company, announced its participation in the Jefferies Global Healthcare Conference. The event will take place in New York on June 6, 2024, at 8:30 a.m. ET. John Celebi, President and CEO, is set to present. The presentation will be webcast live on the investors section of Sensei's website, with a replay available for 90 days.
Sensei Biotherapeutics has released promising data from the Phase 1 dose escalation study of their human monoclonal antibody, SNS-101, targeting the immune checkpoint VISTA. The study shows that SNS-101 is well-tolerated with no dose-limiting toxicities and demonstrates signs of clinical activity, particularly in tumor types typically unresponsive to PD-1 therapies.
Among the 34 patients, promising results were observed in those with microsatellite stable (MSS) endometrial cancer, MSS colorectal cancer, pembrolizumab-resistant renal cell carcinoma, and HPV-positive head and neck cancer.
The pharmacokinetic profile of SNS-101 supports once every three-week dosing, showing linear elimination kinetics and dose-proportional increases in exposure. The ongoing dose expansion portion aims to enroll more patients, with initial data anticipated by the end of 2024.
EGLE Therapeutics announced the appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. Dr. Motlagh's expertise will drive clinical strategy and development, focusing on advancing the company's pipeline in oncology and auto-immunity. Mr. Celebi brings over 25 years of experience in building biotechnology companies. His extensive background includes serving as President and CEO of Sensei Biotherapeutics (NASDAQ: SNSE) and holding leadership positions in various biotech firms.
Sensei Biotherapeutics, Inc. reported financial results for Q1 2024 and recent business highlights, including clinical trial progress, upcoming data presentations, and a strong balance sheet with cash runway into Q4 2025.
FAQ
What is the current stock price of Sensei Biotherapeutics (SNSE)?
What is the market cap of Sensei Biotherapeutics (SNSE)?
What is Sensei Biotherapeutics, Inc.?
What products is Sensei developing?
What is SNS-101?
What are the recent achievements of the company?
Where is Sensei Biotherapeutics headquartered?
What is the TMAb™ platform?
What financial status does Sensei Biotherapeutics have?
Who are Sensei's key collaborators?
What are the anticipated milestones for SNS-101?
Where can I find more information about Sensei Biotherapeutics?
